Gabriel A Vargas

US Patent:

20140065610, Mar 6, 2014

Filed:

Aug 21, 2012

Appl. No.:

13/590211

Inventors:

Laurent Essioux - Attenschwiller, FR
Carsten Horn - Basel, CH
Johann Karl - Peissenberg, DE
Peter Kastner - Muenchen, DE
Fabian Model - Penzberg, DE
Giuseppe Palermo - Basel, CH
Christina Rabe - Bad Heilbrunn, DE
Daniel Umbricht - Zuerich, CH
Gabriel Vargas - Thousand Oaks CA, US
Anne Vogt - Loerrach, DE

International Classification:

G01N 33/68
C12Q 1/68

US Classification:

435 611, 435 74

Abstract:

An in vitro method of predicting whether a patient, having a neurodevelopmental, neurological or neuropsychiatric disorder, will derive a clinical benefit if treated with a glycine reuptake inhibitor (GRI), via determination of the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof and comparison against a representative value, wherein a higher value of the protein concentration in the patient's sample against the representative value is indicative of a patient whom will derive clinical benefit from treatment with GRI.

US Patent:

20230020514, Jan 19, 2023

Filed:

Sep 2, 2022

Appl. No.:

17/902168

Inventors:

- Thousand Oaks CA, US
Eduardo DUNAYEVICH - San Diego CA, US
Robert A. LENZ - Westlake Village CA, US
Gabriel VARGAS - Berkeley CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/28

Abstract:

The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

US Patent:

20190256607, Aug 22, 2019

Filed:

Feb 27, 2019

Appl. No.:

16/287533

Inventors:

- Thousand Oaks CA, US
Eduardo Dunayevich - San Diego CA, US
Robert A. Lenz - Westlake Village CA, US
Gabriel Vargas - Berkeley CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/28

Abstract:

The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.

US Patent:

20160311913, Oct 27, 2016

Filed:

Apr 22, 2016

Appl. No.:

15/136736

Inventors:

- Thousand Oaks CA, US
Eduardo DUNAYEVICH - San Diego CA, US
Robert A. LENZ - Westlake Village CA, US
Gabriel VARGAS - Berkeley CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

C07K 16/28

Abstract:

The present invention relates to methods of migraine prophylaxis using anti-CGRP receptor antibodies or binding fragments. In particular, methods for preventing or reducing the occurrence of migraine headache in a patient in need thereof comprising administering to the patient an anti-CGRP receptor or binding fragment according to specific dosage regimens are disclosed. Pharmaceutical compositions and administration devices comprising anti-CGRP receptor antibodies or binding fragments for use in the methods are also described.